Skip to content

Oral Microbiota and Oral Status of Adult Patients With Autism Spectrum Disorders (MICAA: MICrobiota Autism Adults)

Characterisation of the Oral Microbiota and Oral Status of a Population of Adult Patients With Autism Spectrum Disorders: a Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05910424
Acronym
MICAA
Enrollment
37
Registered
2023-06-18
Start date
2023-11-22
Completion date
2024-04-30
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Keywords

Autism Spectrum Disorder, Oral microbiota, Oral Health

Brief summary

The goals of this pilot study are to assess the presence of harmful germs for gums and to assess oral health in adults with autism spectrum disorder.

Detailed description

Participants or their tutors will fulfill a form with general health information and daily habits. Investigators will : * collect saliva, gum fluid and/ or dental plaque to characterise germs * assess gum health and oral hygiene * register decays, filled and missing teeth.

Interventions

OTHERcollection of saliva, gum fluid and/or dental plaque samples

Non-invasive sampling of dental plaque, crevicular fluid and/or saliva, using an examination probe, paper tips and saliva swabs

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Masking description

No Treatment

Intervention model description

Pilot study concerning adults with autism spectrum disorder

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* A person (or legal representative) who has received full information about the organisation of the research and accept to participate and the use of his or her data. * Adult with autism spectrum disorder, men or women aged between 18 and 60. * Member of a social security scheme or beneficiary of a medical insurance

Exclusion criteria

* Children under 18 with autism spectrum disorder * Use of medication or situations that may affect the microbiota (use of antibiotics, probiotics, steroidal or non-steroidal anti-inflammatory drugs in the last 3 months, strict mouth breathing) * Smoking * Very lingual position of the teeth hindering clinical assessment of the periodontium * Patients who have had periodontal treatment for less than 6 months * Persons covered by articles L. 1121-5 to L. 1121-7 and L1122-2 of the French Public Health Code: * Pregnant women, women in labour or breast-feeding mothers * Persons deprived of their liberty by a judicial or administrative decision * Persons unable to give their consent * Person under psychiatric care by virtue of articles L. 3212-1 and L. 3213-1 of the Public Health Code * Minor (not emancipated)

Design outcomes

Primary

MeasureTime frameDescription
Presence of periodontopathogenic bacteria (harmful for gums)Collection on Day 1Technique used = Polymerase Chain Reaction (PCR) Measure unit = Colony-Forming Unit (CFU)

Secondary

MeasureTime frameDescription
Assessment of the presence of parasites Entamoeba gingivalis subtype 1 (ST1) and subtype 2 (ST2) and Trichomonas tenaxCollection on Day 1Technique = Polymerase Chain Reaction (PCR) Unit = Colony-Forming Unit (CFU)
Assessment of the periodontal status of patients with Autism Spectrum DisorderDay 1Index used = the Dutch Periodontal Index 0 = minimum value, better outcome 4 = maximum value, worse outcome
Assessment of the dental conditionDay 1Dental data will be collected using the Decay-Missing-Filled/Teeth (DMFT) score 0 = minimum value, best outcome 28 = maximum value, worst outcome
Assessment of oral hygieneDay 1Oral hygiene will be assessed using the Silness and Löe plaque index and the lifestyle questionnaire 0 = minimum value, best outcome 3 = maximum value, worst outcome
Collection of data about lifestyle habits (oral and dental hygiene, diet, activity, etc.) and drug treatments that may influence the clinical parameters observedBefore samples collection and clinical examinationData collection via a form fulfilled by the participant or the patient's legal guardian

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026